Cantor Fitzgerald Predicts Cytokinetics FY2025 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Cytokinetics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the biopharmaceutical company will post earnings of ($4.75) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.23) per share.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.09). The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $1.21 million. During the same period last year, the business posted ($1.35) earnings per share. Cytokinetics’s quarterly revenue was up 22.5% on a year-over-year basis.

CYTK has been the subject of a number of other research reports. JMP Securities reissued a “market outperform” rating and issued a $78.00 price objective on shares of Cytokinetics in a research report on Tuesday, January 14th. Stifel Nicolaus initiated coverage on Cytokinetics in a report on Wednesday. They issued a “buy” rating and a $80.00 price target for the company. Royal Bank of Canada raised their price objective on Cytokinetics from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Wednesday, December 18th. HC Wainwright restated a “buy” rating and issued a $120.00 target price on shares of Cytokinetics in a report on Tuesday. Finally, Mizuho upped their price target on Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $83.40.

Cytokinetics Price Performance

NASDAQ:CYTK opened at $46.82 on Wednesday. Cytokinetics has a 12-month low of $44.49 and a 12-month high of $84.92. The firm has a market cap of $5.53 billion, a price-to-earnings ratio of -8.70 and a beta of 0.82. The company’s 50-day moving average is $48.94 and its two-hundred day moving average is $53.03. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93.

Hedge Funds Weigh In On Cytokinetics

Large investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System increased its holdings in Cytokinetics by 0.6% in the third quarter. Louisiana State Employees Retirement System now owns 32,600 shares of the biopharmaceutical company’s stock valued at $1,721,000 after buying an additional 200 shares during the last quarter. UMB Bank n.a. grew its position in shares of Cytokinetics by 65.6% in the 3rd quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 238 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Cytokinetics by 2.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 15,062 shares of the biopharmaceutical company’s stock valued at $795,000 after acquiring an additional 430 shares during the last quarter. MetLife Investment Management LLC raised its position in shares of Cytokinetics by 0.4% during the 3rd quarter. MetLife Investment Management LLC now owns 123,308 shares of the biopharmaceutical company’s stock valued at $6,511,000 after acquiring an additional 538 shares in the last quarter. Finally, Inspire Investing LLC lifted its stake in Cytokinetics by 7.8% during the fourth quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 616 shares during the last quarter.

Insiders Place Their Bets

In related news, EVP Fady Ibraham Malik sold 6,342 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $58.48, for a total value of $370,880.16. Following the sale, the executive vice president now directly owns 113,878 shares of the company’s stock, valued at $6,659,585.44. This represents a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert I. Blum sold 5,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $51.63, for a total transaction of $258,150.00. Following the transaction, the chief executive officer now directly owns 397,456 shares of the company’s stock, valued at approximately $20,520,653.28. This represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 54,216 shares of company stock worth $2,799,276 in the last quarter. 3.40% of the stock is owned by corporate insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.